Expertise in
46
conditions

Dr. Brian J. Byrne

Hematology | Oncology
Mandell & Blau Md's PC
201 N Mountain Rd, 
Plainville, CT 
Offers Telehealth
Expertise in
46
conditions
Mandell & Blau Md's PC
201 N Mountain Rd, 
Plainville, CT 

Overview

Brian Byrne is a Hematologist and an Oncologist practicing medicine in Plainville, Connecticut.

Dr. Byrne is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Cancer.

He is actively involved in clinical research, participating in 5 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Hartford Hospital
The Hospital Of Central Connecticut
Midstate Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Mandell & Blau Md's PC
201 N Mountain Rd, Plainville, CT 06062
Other Locations
Cancer Center of Central Connecticut LLC
55 Meriden Ave Ste 1A, Southington, CT 06489

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 1/Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (26.2 miles away)
203-785-4081
Languages Spoken:
English
See accepted insurances

Farzana Pashankar is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pashankar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Germ Cell Tumor, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
48
conditions
Dr. Todd J. Alekshun
Hematology | Oncology
Expertise in
48
conditions
Dr. Todd J. Alekshun
Hematology | Oncology
Referral may be required

Hartford Healthcare Medical Group

200 Merrow Rd, 
Tolland, CT 
 (27.3 miles away)
860-674-0088
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Todd Alekshun is a Hematologist and an Oncologist practicing medicine in Tolland, Connecticut. Dr. Alekshun is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Lung Adenocarcinoma.

Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Referral may be required

CCMC - Hematology

282 Washington St, 
Hartford, CT 
 (9.1 miles away)
860-545-9630
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Isakoff is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut. Dr. Isakoff is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Isakoff is board certified in American Board Of Pediatrics and American Board Of Pediatrics, Pediatric Hematology & Oncology, Pediatric Hematology Oncology . Dr. Isakoff is currently accepting new patients.

Frequently Asked Questions about Dr. Brian J. Byrne

How do I make an appointment with Dr. Brian J. Byrne?

You can book an appointment with Dr. Brian J. Byrne by calling their office at 860-224-4408. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian J. Byrne a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian J. Byrne is classified as an Distinguished expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian J. Byrne specialize in?

While Dr. Brian J. Byrne is a Hematology, they have specific expertise in Familial Colorectal Cancer, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Brian J. Byrne accept my insurance?

Dr. Brian J. Byrne accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-224-4408 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrne's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 126 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile